✦ LIBER ✦

Hepatocellular carcinoma treated with sorafenib

✍ Scribed by G. Han; Y. Zhao; X. Qi; D. Fan

Book ID: 108606470
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 78 KB
Volume: 34
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2011.04852.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatocellular carcinoma treated with so

Hepatocellular carcinoma treated with sorafenib: authors’ reply

✍ M. Peck-Radosavljevic; M. Pinter; W. Sieghart 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Prognostic factors in patients with adva

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

✍ M. Pinter; W. Sieghart; F. Hucke; I. Graziadei; W. Vogel; A. Maieron; R. Königsb 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

Sorafenib combined with cryoablation to

Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma

✍ Hong Ni; Mao Yang; Zhi Guo; Ti Zhang 📂 Article 📅 2011 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 521 KB

Computed tomography findings of sorafeni

Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma

✍ Min Ju Kim; Joon-Il Choi; Jong Seok Lee; Joong-Won Park 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 451 KB

Complete remission of unresectable hepat

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

✍ Sean Xiang Wang; Abigail Byrnes; Sadhna Verma; John R. Pancoast; Olivier Rixe 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 300 KB

Comparison of tumor response by Response

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

✍ Julien Edeline; Eveline Boucher; Yan Rolland; Elodie Vauléon; Marc Pracht; Chris 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

## Abstract ## BACKGROUND: A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed